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Iron-mediated injury plays an important role in a number of heart disorders. Studies on heart iron are therefore crucial for understanding the
causes of excessive heart iron. Heart cells have the ability to accumulate transferrin-bound-iron via the transferrin receptor and non-transferrin-
bound-iron probably via the L-type Ca2+ channel and the divalent metal transporter1. However, little is known about the mechanisms of iron
export in the heart cells. Here, we investigated expression of iron exporters including ferroportin 1 (Fpn1), ceruloplasmin (CP) and hephaestin
(Heph) and provided evidence for their existence in the heart. We demonstrated that iron has a significant effect on expression of Fpn1 and CP, but
not Heph. Treatment of a high-iron diet induced a significant increase in Fpn1, a decrease in CP but no change in Heph mRNA and protein. The
control of Fpn1 and CP protein expression by iron was parallel to that of their mRNA expression, suggesting a transcriptional regulation of Fpn1
and CP by iron. The existence of these proteins in the heart implies that they might have a role in heart iron homeostasis.
© 2007 Elsevier B.V. All rights reserved.Keywords: Ferroportin1; Ceruloplasmin; Hephaestin; Transferrin receptor; Heart; Iron metabolism1. Introduction
Iron is an essential trace element in humans. As in all cells,
heart cells require iron for many aspects of their physiology. OnAbbreviations: CP, Ceruloplasmin; DMT1, Divalent metal transporter 1;
Fpn1, Ferroportin 1; Hb, Hemoglobin; Hct, Hematocrit; Heph, Hephaestin;
IREG1, Iron-regulated transporter 1; IRP, Iron regulatory protein; LVDCC, L-
type voltage-dependent Ca2+ channel; MTP1, Metal transport protein 1; NTBI,
Non-transferrin-bound iron; SD rats, Sprague–Dawley rats; SDS, Sodium
dodecyl sulfate; SSC, Sodium chloride-sodium citrate; TfR1, Transferrin
receptor 1; Tf-Fe, Transferrin-bound iron; TIBC, Total iron-binding capacity
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doi:10.1016/j.bbadis.2007.02.006the other hand, an excess of iron in the heart can be potentially
harmful via the generation of reactive oxygen species. A vast
amount of literature shows that iron-mediated injury plays an
important role in the development of a number of heart disorders,
including heart ischemia–reperfusion injury [1,2], acute myo-
cardial infarction [3,4] and coronary heart diseases [5]. Iron may
also be involved in the development of cardiotoxicity induced by
doxorubicin [6–9] and is associated with significant cardiovas-
cular morbidity and mortality in hemochromatosis [10,11] and
beta-thalassemia [12]. Iron chelation therapy can significantly
improve heart reperfusion injury, the prognosis in thalassemia
patients and the endothelial function of patients with coronary
artery diseases [13–16]. This implies a key role of iron in the
pathogenesis of these diseases. Therefore, study on the
mechanism of iron balance in the heart is crucial for the
understanding of the cause of excessive iron accumulation in the
heart as well as the development of new approaches for the
treatment of patients with heart iron overload.
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precisely regulated. Transferrin receptor (TfR) and ferritin are
two important proteins that play a primary role in the manage-
ment of cell iron. By controlling the expression of these two
proteins, cells can determine the amount of iron acquired and
sequestered [17–19]. In most types of cells, the coordinated
control of TfR and ferritin by cellular iron occurs at the post-
transcriptional level and is mediated by the cytoplasmic RNA
binding protein, known as the iron regulatory protein (IRP)
[20,21]. In addition to TfR mediated transferrin-bound iron
(Tf-Fe) uptake, the heart cells are able to assimilate a large
amount of non-transferrin-bound iron (NTBI) [22], probably via
the L-type Ca2+ channel (or the L-type voltage-dependent Ca2+
channel, LVDCC), the voltage-independent uptake system, and
the divalent metal transporter1 (DMT1) [23–26]. In addition to
iron uptake (TfR, LVDCC and DMT1) and storage (ferritin),
cellular iron balance in the heart also depends on the amount of
iron export from the cells. Currently, we know little about how
iron is discharged from the heart cells and which molecules are
involved in this process. In this study, we therefore investigated
the expression of iron efflux proteins including ferroportin 1
(Fpn1), ceruloplasmin (CP) and hephaestin (Heph) and the
effects of iron on their expression in the heart.
CP is an abundant plasma protein which is mainly
synthesized in the hepatocytes. It is widely believed that CP
and Heph (a CP homologue) have a role in iron efflux from
the cells in the peripheral tissues as well as in the central
nervous system [27,28]. Fpn1 (also known as IREG1 or
MTP1) is a newly discovered iron transport protein that was
first identified as a duodenal iron export molecule [29]. Fpn1
may work with Heph or CP in the iron transport from the
enterocytes into circulation [30]. It has been suggested that
they might function in the iron transport across the abluminal
membrane of the blood–brain barrier cells and from other
types of cells [31,32].
In this study, we demonstrated that the heart is able to
express all these three proteins. Their existence in the heart
suggested their potential role in iron release from the heart cells.
The data also demonstrated that iron has a significant effect on
the expression of Fpn1 and CP, but not Heph, and showed that
the regulation of Fpn1 and CP by iron might occur at the
transcriptional level. The different effects of iron on Fpn1, Heph
and CP expression implied that the Fpn1/Heph pathway might
play a major role in cell iron export and that Heph might not be
rate limiting for iron export from the heart cells.2. Materials and methods
2.1. Materials
Unless otherwise stated, all chemicals were obtained from Sigma Chemical
Co., St. Louis, MO, USA. Agarose, Ethidium Bromide and prestained protein
marker were purchased from Bio-Rad Laboratories, Hercules, CA, USA and
Trizol® Reagent was from Invitrogen., Carlsbad, CA, USA. ExpressHyb
hybridization solution was obtained from Clontech, Palo Alto, CA, USA, and
Prime-a-Gene labeling system was from Promega, WI, USA. Micro Spin G-50
column, Hybond-N membrane, [α-32P]dCTP and ECL western blotting analysis
system kit were purchased from Amersham Biosciences, England. The ABCReagent and DAB kit were products of Vector, Burlingame, USA. The rabbit
anti-mouse Fpn1 and Heph antiserum were purchased from Alpha Diagnostics
Intl. Inc., San Antonio, USA and mouse anti rat CP IgG1 and CD71 monoclonal
antibody from BD Biosciences Pharmiegen, Franklin Lakes, USA. Male
Sprague–Dawley (SD) rats were supplied by the Centralized Animal Facilities
of The Hong Kong Polytechnic University. The Health Department of Hong
Kong Government and Animal Ethics Committee of The Hong Kong
Polytechnic University approved the use of animals for this study. All the
animals were housed in pairs in stainless steel cages at 21±2 °C with relative
humidity of 60–65% and alternating 12-h periods of light (7:00–19:00) and
darkness (19:00–7:00).
2.2. Experimental design and sampling of blood and tissue
To investigate the effect of variations in dietary iron on the Fpn1, CP and
Heph gene expression in the heart, male SD rats (21 days of age) in the control
(n=6), the high-iron (n=6) and the low-iron (n=6) groups were fed respectively
with the Basal Purified Diet (containing 60 mg Fe/kg) (PMI, Catalog #7024), the
Basal Purified Diet supplemented with 2.5% carbonyl iron (PMI, Catalog
#43784) and the Low Iron Purified Diet containing no added iron (PMI, Catalog
#7444) (residue of 10 mg Fe/kg diet) for 6 weeks. At the end of the period, the
animals were anesthetized with 1% pentobarbital sodium (40 mg/kg body
weight, i.p.) and decapitated. Blood samples were then collected into
heparinized syringes and aliquots were taken immediately for the determination
of hemoglobin (Hb) concentration and hematocrit (Hct). The serum samples
were analyzed for serum iron, total iron-binding capacity (TIBC) and transferrin
saturation (serum iron/TIBC). To remove all the blood from the hearts, the rats
were intracardially perfused with heparinized PBS for 5 min. After perfusion,
the hearts were collected, excised and rinsed in PBS, blotted dry and weighed
according to Zaman et al. [9]. Portions of the left ventricle were used
immediately for total RNA extraction and protein determination. The remaining
ventricle and liver were frozen in liquid nitrogen and stored at −70 °C for the
measurement of non-heme iron.
2.3. RNA purification, generation of specific probes, and northern blot
assay
Total RNA was isolated from the left ventricular myocardium using the
Trizol® reagent according to the manufacturer's instructions. The relative purity
of the isolated RNA was assessed spectrophotometrically and the ratio of
A260 nm to A280 nm exceeded 1.9 for all preparations. Special 32P-labeled
probes corresponding to positions 1298–1733 of Fpn1 (Genbank, AF394785),
3659–4201 of Heph (Genbank, AF246120), 1133–1518 (Genbank, L33869) of
CP and 5–574 of TfR1 (Genbank, M58040) were generated. The RNA samples
(30 μg) were electropherosed on 1.2% formaldehyde-agarose gels, transferred to
the Hybond-N membranes and then immobilized by using an UV cross-linker
(Fisher). The blots were prehybridized at 65 °C in the ExpressHyb hybridization
solution for 1 h, and then hybridized overnight at 65 °C in the same solution
containing the 32P-labeled probe by using the Prime-a-Gene labeling system
(Promega, WI, USA). After three 10-min washes with 2× standard sodium
chloride-sodium citrate (SSC) containing 0.05% sodium dodecyl sulfate (SDS)
at room temperature, the blots were washed in 0.1× SSC containing 0.1% SDS
with continuous shaking at 50–60 °C for 10 min for 3–4 times. Radioactivity
was then detected by a phosphorimager and quantified using the ImageQuant
software (Molecular Dynamics, Sunnyvale, CA). For normalization, the blot
was stripped and reprobed with β-actin probe corresponding to the position
474–736 of the rat β-actin (Genbank, NM031144). The results were expressed
as the ratio to β-actin.
2.4. Western blot analysis
The left ventricular myocardium was homogenized in RIPA buffer
containing 1% Triton X-100. After centrifugation at 10,000×g for 30 min at
4 °C, the supernatant was collected. Protein concentration in the supernatant was
assayed. Aliquots of the total cell extract containing 10 μg of protein were
loaded on a single track of 10% SDS-PAGE under reducing conditions and
transferred by electroblotting onto the PVDF membrane (Hybond-P) overnight
Fig. 1. Effects of iron on expression of ferroportin1 mRNA and protein in the
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by using 5% blocking reagent in a solution of Tris-buffered salt with Tween 20
(TBS-T) (20 mM Tris–Cl, pH 7.6, 137 mM NaCl, 0.1% Tween 20) for 2 h at
room temperature, then incubated with rabbit anti-mouse Fpn1 and Heph
antiserum (1:5000), mouse anti rat CP IgG1 and CD71 monoclonal antibody
(1:1000) overnight at 4 °C. After washing with TBS-T, the blots were incubated
in anti-rabbit secondary antibody conjugated horseradish peroxide (1:5000)
(Amersham, UK) for 1 h at room temperature. Immunoreactive proteins were
detected by using the enhanced chemiluminescence method (ECL kit,
Amersham, UK), and quantified by transmittance densitometry using volume
integration with the LumiAnalyst Image Analysis software (Roche Molecular
Biochemical) to determine the enrichment of proteins in the hearts. To ensure an
even loading of the samples, the same membrane was probed with rabbit anti
β-actin polyclonal antibody (Sigma-Aldrich, MO) at a 1:5000 dilution.
2.5. Analytical methods
Hemoglobin concentration was determined by the cyanmethemoglobin
method [33,34]. Hematocrit was measured using the microhematocrit centrifuge
and plasma iron and total iron-binding capacity were determined using
commercial kits (Sigma). Non-heme iron concentrations of tissues were
measured as described previously [33,34]. The results were expressed as
Means±SEM. Difference between the means was determined by one-way
ANOVA followed by a Student–Newman–Keuls test for multiple comparisons.
A probability value of P<0.05 was taken to be statistically significant.heart. Expression of Fpn1 mRNA and protein was determined by northern blot
and western blot analysis in the rats fed with the control diet (CN), the iron-
deficient (LF) and iron-overload (HF) diets for 6 weeks. (A) Representative
blots of Fpn1 and β-actin mRNAs and proteins (molecular masses of 60 and
45 kDa, respectively). (B) Relative levels of Fpn1 mRNA and protein. Data are
means±SEM (% control, n=6). **P<0.01 vs. the control.3. Results
3.1. Effect of iron diets on biochemical parameters
In the high-iron rats, the Hb, Hct, Tf saturation and the non-
heme iron level in the heart and liver were significantly higher
than those in the control rats (P<0.01, Table 1). The iron
content in the heart increased 4.2-fold above that of the controls.
These findings show that a high-iron loaded heart model was
successfully developed. Rats fed with an iron-deficient diet for
6 weeks had significantly lower body weight, Hb, Hct, Tf
saturation and non-heme iron levels in the heart and liver as
compared to the controls (P<0.01, Table 1). The heart weight
and the heart/body weight were higher in the iron-deficient rats
than in the controls (P<0.01). The data suggest that rats fed
with the iron deficient diet did develop an iron deficiency with
anaemia.Table 1
Hematological variables, liver non-heme iron in the control, iron deficient, and
iron overload rats
Control
(n=6)
Iron deficiency
(n=6)
Iron overload
(n=6)
Body weight (g) 327±4.27 270±4.48 a 340±7.11
Hct (%) 43.50±2.11 17.67±0.99 a 48.88±1.17 a
Hb (g/dL) 17.96±0.59 5.27±0.38 a 19.63±0.30 a
Serum iron (mmol/L) 24.67±0.88 3.11±0.53 a 48.80±2.11 a
TIBC (mmol/L) 67.79±1.29 109±3.27 a 69.69±1.34
Transferrin saturation (%) 36.36±0.81 2.93±0.54 a 70.20±3.57 a
Liver iron (mg/g dry weight) 0.27±0.01 0.07±0.01 a 2.66±0.13 a
Heart iron (mg/g dry weight) 0.073±0.008 0.032±0.003 a 0.379±0.016 a
Heart weight (g) 1.01±0.05 1.33±0.05 a 0.92±0.04
Heart:body weight (×10−3) 3.02±0.18 4.91±0.26 a 2.69±0.13
a P<0.01 vs. the controls.3.2. Effect of iron status on expression of ferroportin1,
hephaestin and ceruloplasmin mRNA and protein
Northern blot analysis was performed to determine the effect
of iron on the expression of Fpn1, Heph and CP mRNA.
Representative northern blots showing the expression of Fpn1,
Heph and CP mRNAs were presented in Figs. 1A, 2A and 3A.
Quantified mRNA levels relative to β-actin for each transcript
from the independent samples were shown in Figs. 1B, 2B and
3B. The transcript level of Fpn1 mRNA decreased significantly
(58±3%) in the iron-deficient rats and increased (253±20%) in
the iron-overloaded rats (Fig. 1B, all P<0.01) as compared to
the control. In contrast, the level of CP mRNAwas significantly
higher (135±2%) in the iron-deficient rats and lower (89±5%)
in the iron-overload rats than that in the controls (Fig. 3B,
P<0.05). This finding is similar to the result reported by other
studies [35,36]. No significant differences in Heph mRNAwere
found among the iron-deficient, the iron-overload and the
control animals (Fig. 2B).
To determine the effect of iron on Fpn1, CP and Heph
proteins, western blot analysis was conducted. It was found that
the amount of Fpn1 protein decreased to 74±8% of the controls
after the rats were fed with a low-iron diet. After the rats were
fed with a high-iron diet, the FP1 protein increased to 230±20%
of the controls (Fig. 1B, all P<0.01). As shown in Fig. 3, the
regulation of CP protein expression was parallel to that of the
mRNA expression. After the rats were fed with a low-iron diet,
the CP protein increased to 142±3% of the controls (Fig. 3B,
P<0.05); in the high-iron group the CP protein decreased to
Fig. 4. Effects of iron on expression of transferrin receptor 1 mRNA and protein
in the heart. Expression of TfR1 mRNA and protein was determined by northern
blot and western blot analysis in the rats fed with the control diet (CN), the iron-
deficient (LF) and iron-overload (HF) diets for 6 weeks. (A) Representative
blots of TfR1 and β-actin mRNAs and proteins. (B) Relative levels of TfR1
mRNA and protein. Data are means±SEM (% control, n=6). **P < 0.01 vs. the
control.
Fig. 2. Effects of iron on expression of hephaestin mRNA and protein in the
heart. Expression of Heph mRNA and protein was determined by northern blot
and western blot analysis in the rats fed with the control diet (CN), the iron-
deficient (LF) and iron-overload (HF) diets for 6 weeks. (A) Representative
blots of Heph and β-actin mRNAs and proteins. (B) Relative levels of Heph
mRNA and protein. Data are means±SEM (% control, n=6). *P<0.05,
**P<0.01 vs. the control.
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rats fed with a low-iron or high-iron diet was lower than that in
the control animals, however, no significant differences wereFig. 3. Effects of iron on expression of ceruloplasmin mRNA and protein in the
heart. Expression of Heph mRNA and protein was determined by northern blot
and western blot analysis in the rats fed with the control diet (CN), the iron-
deficient (LF) and iron-overload (HF) diets for 6 weeks. (A) Representative
blots of CP and β-actin mRNAs and proteins. (B) Relative levels of CP mRNA
and protein. Data are means±SEM (% control, n=6). *P<0.05 vs. the control.found among them. These results show that iron has a negative
effect on CP, a positive effect on Fpn1 and no effect on Heph
expression in the heart.
3.3. Effect of iron on expression of transferrin receptor 1
mRNA and protein
For comparison, we also analyzed the expression of TfR1
mRNA and protein in the control, low-iron and high-iron rats.
In the high-iron rats, there was an increase in the iron content in
the heart. The northern blotting and western blotting results
showed that the expression of TfR1 mRNA and protein
significantly declined about 35% and 45% to the control;
respectively (Fig. 4). In the iron-deficiency models, iron in the
heart decreased significantly and the level of TfR1 mRNA and
protein increased remarkably, being about 2.7 times(mRNA)
and 2.4 times(protein) relative to the control rats. These results
demonstrated that iron has a significant effect on the expression
of TfR1 in the heart.
4. Discussion
In this study, we investigated the expression of iron efflux
transporters including ferroportin 1 (Fpn1), ceruloplasmin
(CP), and hephaestin (Heph) and the effects of iron on their
expression in the heart. To our knowledge, this is the first
report on the expression of Fpn1 and Heph mRNA and protein
in the rat heart. Northern and western blotting results showed
that the heart is able to express Fpn1 and Heph. The existence
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might have a role in iron homeostasis in the heart, and is
possibly involved in the iron export from the heart cells. The
data obtained also demonstrated that iron has a significant
effect on the expression of Fpn1 and CP, but not Heph. In the
rats treated with a high-iron diet for 6 weeks, the transcript
levels of Fpn1 and CP mRNA were found to be significantly
increased and decreased; respectively. The control of Fpn1 and
CP protein expression by iron was parallel to that of their
mRNA expression, suggesting that the regulation of Fpn1 and
CP by iron in the heart might occur at the transcriptional level.
No significant changes in Heph mRNA and protein expression
were found in the rats treated with a high- or low-iron diet.
Ferroportin 1, also known as metal transport protein 1
(MTP1), iron-regulated transporter 1 (IREG1), or Slc11a3, is a
newly identified cellular iron exporter [29,37,38]. The mRNA
transcript of FP1 contains an iron responsive element (IRE) in
its 5′ untranslated region [29,37,38]. This structure implies
that the Fpn1 expression might be regulated at the translational
level in a manner similar to other 5′UTR-IRE-regulated genes,
including ferritin, mitochondrial aconitase, erythroid 5-amino-
levulinate synthase, and succinate dehydrogenase [38]. In an
investigation on the functional role of genomic SLC40A1
elements (Fpn1 is the product of the SLC40A1 gene) in
response to iron in human hepatoma (HepG2), intestinal
carcinoma (Caco2) and lympho-monocytic (U937) cell lines,
Lymboussaki et al. [39] demonstrated directly that the IRE in
Fpn1 mRNA is functional and that it controls Fpn1 expression
through the cytoplasmic IRP. However, data that are not
consistent with this IRE/IRP-mediated translational control
have also been reported. The findings in intestinal enterocytes,
Caco2 intestinal cells [37,40], murine J774 macrophages [41],
and human alveolar macrophages [42] show that there is also a
transcriptional mechanism that controls Fpn1 expression in
these cells. The results in the present study are in agreement
with the above findings, implying the existence of a
transcriptional control of Fpn1 expression in the heart.
Based on the published data and our results, it seems likely
that both of the transcriptional and translational (IRP/IRE
pathway) mechanisms of Fpn1 expression operate in a tissue-
specific manner [29,38]. In addition, the Fpn1 protein level in
the heart may be critically controlled by hepcidin, a newly
discovered iron regulation peptide [43], through its effect on
the degradation of Fpn1 [44]. The increased Fpn1 protein
might be partly due to the decreased hepcidin level induced by
a high-iron diet.
Fpn1 mediated-iron export has been demonstrated by the
increased iron efflux in the iron-loaded Xenopus oocytes
expressing Fpn1 [29,38], and by the cellular iron depletion in
HEK293T cells transiently transfected with the full-length FP1
cDNA [37]. Ceruloplasmin is an abundant serum alpha-2
glycoprotein and has a molecular mass of approximately
132 kDa. It is widely accepted that CP has a role in iron efflux
from cells in the peripheral tissues as well as in the central
nervous system [27,28]. Heph is a transmembrane-bound CP
homologue protein, which is expressed in the villus of the small
intestine [30,45]. The diminished transport of iron from themucosal cell to the circulation in sla mice implies that Heph has
a role in the physiological iron absorption in the small intestine
[30,46]. However, Heph contains only one predicted carboxy-
terminal transmembrane domain. Heph itself is therefore
unlikely to be a membrane iron transporter [30,47]. CP or
Heph may work together with FP1 in the iron transport from the
enterocytes into the circulation [30,47]. It has also been
proposed that the Fpn1/Heph or Fpn1/CP systems might have
a role in the iron transport across the abluminal membrane of the
blood–brain barrier cells and in the iron release from other types
of cells [31,32,48].
In summary, the present study provided evidence for the
existence of iron efflux proteins including Fpn1, CP and their
homologue Heph in the heart. This implied that these proteins
might play a role in iron homeostasis in heart. Findings also
showed that the regulation of Fpn1 and CP expression by iron
might occur at the transcriptional level in the heart. Treatment
with a high-iron (or low-iron) diet for 6 weeks led to a significant
increase (or decrease) in Fpn1, a remarkable decrease (or
increase) in CP, and no change in Heph mRNAs and proteins'
expression. These findings suggested that the Fpn1/Heph
pathway might play a major role in the iron export from the
heart cells and that Heph might not play a primary regulatory
role and might not be rate limiting in this process of iron export
from the heart cells.
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